SCHEMBL2377643

SCHEMBL2377643

COc1ccc(CN(Cc2ccc(OC)cc2)c2ncc(-c3nc(N4CCOCC4)nc4c3CCN4c3ccc(C(=O)N4CCN(c5ccccn5)CC4)cc3F)cn2)cc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIK3CA P42336 11/20 0.59
PIK3R1 P27986 2/20 0.45
CYP2C9 P11712 3/20 0.42
CYP2C19 P33261 2/20 0.42
ALDH1A1 P00352 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP3A4 P08684 1/20 0.42
KDM4E B2RXH2 1/20 0.42
NPSR1 Q6W5P4 2/20 0.40
HPGD P15428 2/20 0.40
HSD17B10 Q99714 2/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
PIK3CB P42338 1/20 0.40
MAPK1 P28482 2/20 0.40
LMNA P02545 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2376345 0.91 PIK3CA (0.57) PIK3CAPIK3R1CYP2C9CYP2C19ALDH1A1
SCHEMBL2376624 0.91 PIK3CA (0.61) PIK3CAPIK3R1PIK3CB
SCHEMBL2378960 0.90 PIK3CA (0.63) PIK3CAPIK3R1SMN1; SMN2HPGDPIK3CB
SCHEMBL2378207 0.90 PIK3CA (0.58) PIK3CAPIK3R1PIK3CB
SCHEMBL2376526 0.89 PIK3CA (0.63) PIK3CAPIK3R1SMN1; SMN2HPGDPIK3CB
SCHEMBL2378123 0.89 PIK3CA (0.60) PIK3CAPIK3R1CYP2C9CYP3A4PIK3CB
SCHEMBL2378623 0.88 PIK3CA (0.58) PIK3CAPIK3R1KDM4EPIK3CBLMNA
SCHEMBL2379592 0.88 PIK3CA (0.60) PIK3CAPIK3R1PIK3CB
SCHEMBL2378030 0.87 PIK3CA (0.58) PIK3CAPIK3R1PIK3CB
SCHEMBL2377990 0.86 PIK3CA (0.58) PIK3CAPIK3R1SMN1; SMN2HPGDPIK3CB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2050749-B1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI PHARMACEUTICAL CO LTD (JP) 2017-11-22 EP disclosed
US-8022205-B2 Pyrimidine derivatives as PI3K inhibitor and use thereof CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2011-09-20 US disclosed
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2010-03-18 US disclosed
EP-2050749-A1 PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2009-04-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069629-A1 PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF PIK3CA, AKT3, AKT1 PIK3CA 1/4885PIK3R1 5/4885CYP2C9 1768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.